The recent withdrawal of Merck's blockbuster COX-2 inhibitor, the anti-arthritis pain reliever Vioxx (rofecoxib), was a major blow to a number of interested parties. Merck, of course, took the biggest hit. But the millions of arthritis sufferers who depended on reliable and safe relief from pain since Vioxx's approval in 1999 are also confused and upset, and the federal drug regulators at the FDA are in the midst of a losing streak of unprecedented proportions.
The recent withdrawal of Merck's blockbuster COX-2 inhibitor, the anti-arthritis pain reliever Vioxx (rofecoxib), was a major blow to a number of interested parties. Merck, of course, took the biggest hit. But the millions of arthritis sufferers who depended on reliable and safe relief from pain since Vioxx's approval in 1999 are also confused and upset, and the federal drug regulators at the FDA are in the midst of a losing streak of unprecedented proportions.